Table 2:
Summary of Lipid Outcomes
Pre-atorvastatin | Pre-to post- atorvastatin change | ||||
---|---|---|---|---|---|
Lipid Outcomes | N | Median | 95% CI for Median | Median (Q1, Q3) |
95% CI for Median |
Fasting Total Cholesterol (mg/dL) | 66 | 101.5 | (96.0, 112.0) | −39.0 (−58.0, −25.0) |
(−46.0, −32.0) |
LP-PLA2 (ng/mL) | 67 | 135.7 | (123.6, 150.9) | −40.4 (−68.6, −16,4) |
(−51.4, −26.0) |
Oxidized LDL (u/L) | 67 | 44.9 | (41.8, 48.1) | −13.8 (−18.7, −8.7) |
(−15.8, −12.3) |
Note: LP-PLA2: Lipoprotein-associated phospholipase A2. LDL: Low-density lipoprotein.